UltraSight Joins Butterfly Garden to Expand AI Real-Time Guidance Across Point of Care Ultrasound Devices
UltraSight Joins Butterfly Garden to Expand AI Real-Time Guidance Across Point of Care Ultrasound Devices
Leveraging Butterfly Network's platform, UltraSight seeks to enable patients to access cardiac imaging with real-time AI guidance
利用Butterfly Network的平台，UltraSight旨在通過實時人工智能指導使患者能夠接受心臟成像
TEL AVIV, Israel, June 27, 2024 /PRNewswire/ -- Today, UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial intelligence, announced it has joined Butterfly Garden, an artificial intelligence (AI) Marketplace launched by Butterfly Network, Inc. ("Butterfly") (NYSE: BFLY), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software.
2024年6月27日，以色列特拉維夫 / PRNewswire – 今天,UltraSight爲數字醫療先鋒，通過人工智能的強大力量改變心臟成像，宣佈已加入Butterfly GardenButterfly GardenButterfly Network，Inc.推出的人工智能（AI）市場領銜的數字醫療公司Butterfly Network，Inc.（“Butterfly”）（紐交所：BFLY），它通過便攜式半導體超聲技術和直觀的軟件改變護理
UltraSight and Butterfly have partnered to increase patient access to cardiac care by enabling more healthcare professionals to perform cardiac ultrasound. Subject to regulatory approvals and authorizations, UltraSight aims to integrate and deploy its real-time AI guidance software on Butterfly's imaging platform and build the software for use with Butterfly's single-probe, whole-body handheld ultrasound system.
UltraSight和Butterfly合作，旨在通過使更多的醫療保健專業人員進行心臟超聲檢查，從而增加患者接受心臟護理的機會。
Cardiovascular disease (CVD) is the leading global cause of death, accounting for an estimated 18 million deaths yearly. Today patients face significant delays in receiving crucial cardiac testing due to a fragmented market full of system bottlenecks, in addition to a national shortage of expert sonographers.
心血管疾病（CVD）是全球主要的死亡原因，每年約有1800萬人死亡。由於市場的碎片化和國家缺乏專業的超聲技師，患者今天面臨重大的心臟測試延遲。
UltraSight's mission is to empower any medical professional, including novice users with no prior sonography experience, to confidently conduct echocardiographic examinations and capture diagnostic quality cardiac ultrasound images at the point of care. Achieving compatibility with the most prominent handheld ultrasound device companies in the market, such as Butterfly, facilitates the company's goal of increasing access to cardiac care and reducing system bottlenecks for patients.
UltraSight的使命是賦予任何醫療專業人員（包括沒有超聲經驗的新手用戶）自信地進行心臟超聲檢查並在治療點捕捉診斷質量的心臟超聲圖像。與市場上最突出的手持超聲設備公司（如Butterfly）兼容，有助於該公司實現增加心臟護理的目標並減少患者的系統瓶頸。
"Joining the Butterfly Garden marks an important moment in our mission to revolutionize cardiac care," said Davidi Vortman, CEO of UltraSight. "By integrating our real-time AI guidance software with Butterfly's cutting-edge ultrasound technology, we are poised to transform the landscape of cardiac imaging. This collaboration will empower healthcare professionals, regardless of their experience level, to perform accurate and timely cardiac ultrasound exams at the point of care. Together, we will break down existing barriers in cardiac care, ensuring that more patients receive the critical diagnostics they need, when and where they need it most."
UltraSight首席執行官Davidi Vortman表示：“加入Butterfly Garden標誌着我們改變心臟護理的使命中的重要時刻。通過將我們的實時人工智能指導軟件與Butterfly的尖端超聲技術集成，我們將改變心臟成像的格局。此次合作將賦予醫療保健專業人員進行準確和及時的心臟超聲檢查的能力，無論他們的經驗水平如何。我們將共同打破心臟護理中現有的障礙，確保更多的患者在最需要的時候獲得關鍵的診斷。”
"We are thrilled to partner with UltraSight to bring their AI guidance software to Butterfly devices in an effort to mitigate the pressing issue of sonographer shortages, among other workforce challenges, impacting medical communities around the world," said Darius Shahida, chief strategy officer of Butterfly Network. "UltraSight and Butterfly are jointly dedicated to making healthcare more efficient, effective and accessible through high-quality ultrasound that's easy-to-use and globally available."
Butterfly Network首席策略官Darius Shahida表示：“我們很高興與UltraSight合作，將他們的人工智能指導軟件帶到Butterfly設備中，以解決影響全球醫療社區的超聲技師短缺等人力資源挑戰。UltraSight和Butterfly共同致力於使醫療保健更高效，更有效，更可獲得，通過易於使用且在全球範圍內可用的高質量超聲技術。”
In August 2023, Butterfly Network launched Butterfly Garden, allowing third-party developers access to its proprietary SDK and APIs to build new AI applications that work in conjunction with Butterfly's imaging platform, bringing with it access to the largest point-of-care ultrasound customer base. UltraSight, with capabilities to provide more medical professionals with the ability to take high-quality diagnostic images of the heart, has the potential to close the gap between novice and skilled Butterfly ultrasound users, and is an ideal match for the program.
2023年8月，Butterfly Network發佈了Butterfly Garden，允許第三方開發人員訪問其專有的SDK和API，以構建與Butterfly成像平台配合使用的新AI應用程序，帶來最大的治療點超聲客戶基礎。具有提供更多醫療專業人員拍攝高質量心臟診斷圖像的能力，UltraSight有望縮小超聲新手和熟練Butterfly超聲用戶之間的差距，是該計劃的理想匹配。推出Butterfly
When paired with ultrasound devices, and following the appropriate regulatory clearance for each device, UltraSight's underlying AI neural network can predict the position of the ultrasound probe relative to the heart based on the ultrasound video stream and guide the user on maneuvering the probe to capture diagnostic quality cardiac images.
在配對超聲設備時，並根據每個設備的適當監管事項獲得批准後，UltraSight的基礎人工智能神經網絡可以基於超聲視頻流預測超聲探頭相對於心臟的位置，並引導用戶操縱探頭以捕獲診斷質量的心臟圖像。
UltraSight's partnership with Butterfly follows a series of recent collaborations with other industry leaders such as Mayo Clinic and EchoNous. For more information about UltraSight, visit . For more information about Butterfly, visit .
UltraSight與Butterfly的合作是其與其他行業領袖（例如Mayo Clinic和EchoNous）最近的一系列合作之後的結果。有關UltraSight的更多信息，請訪問。有關Butterfly的更多信息，請訪問
About UltraSight
關於UltraSight
UltraSight's mission is to make diagnostic imaging more accessible by empowering medical professionals to successfully acquire timely and accurate cardiac ultrasound images anywhere. UltraSight's AI-driven software offers real-time guidance, making cardiac ultrasound accessible and efficient, which may lead to quicker diagnoses and improved patient care. In 2022, UltraSight won the Bristol Myers Squibb Improving Cardiovascular Disease Outcomes Challenge as the most "innovative cardiac technology." Additionally, the company was awarded a patent for its real-time guidance solution for ultrasound devices. UltraSight's software has FDA 510(k) Clearance, is UKCA and CE Marked, and has Israeli AMAR Clearance to assist medical professionals in performing cardiac ultrasound scans. For more news and information, visit our website or follow UltraSight on LinkedIn and Twitter
UltraSight的使命是通過賦予醫療專業人士成功獲取準時準確的心臟超聲圖像來使診斷成像更易於接觸。 UltraSight的人工智能驅動軟件提供實時指導，使心臟超聲成像變得易於接觸和高效，這可能會導致更快的診斷和改善患者護理。在2022年，UltraSight贏得了Bristol Myers Squibb改善心血管疾病結果挑戰賽，成爲最具“創新性的心臟技術”。此外，該公司還因其超聲設備實時指導解決方案獲得了一項專利。UltraSight的軟件具有FDA 510（k）清除，通過UKCA和CE標記，並獲得以色列AMAR清除，以幫助醫療專業人士執行心臟超聲掃描。有關更多新聞和信息，請訪問我們的網站。或訪問UltraSight的網站關注UltraSightLinkedIn和 推特
About Butterfly Network
關於Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world's first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore's Law, to launch its second-generation Butterfly iQ+ in 2020, and third-generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME's Best Inventions, Fast Company's World Changing Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: .
Butterfly Network由Jonathan Rothberg博士於2011年創立，是一家數字醫療公司，旨在通過使高質量超聲成像價格合理、易於使用、全球易於接觸、智能連接等方式民主化醫學成像，包括全球47億無法獲得超聲成像服務的人群。 Butterfly利用半導體技術創造了世界上第一個手持式單探頭全身超聲系統Butterfly iQ。該公司不斷創新，利用摩爾定律的好處，在2020年推出了第二代Butterfly iQ+，並在2024年推出了第三代iQ3，每個版本都具有處理能力和性能增強。這種破壞性技術已被認可爲TIME最佳發明、Fast Company世界改變想法、CNBC破壞者50和MedTech Breakthrough Awards等其他讚譽。憑藉其專有的芯片超聲技術、智能軟件和教育服務，Butterfly正在爲全球早期檢測和遠程健康管理鋪平道路。Butterfly設備已在非洲、亞洲、澳大利亞、歐洲、中東、北美和南美等地區開放給受過培訓的醫療保健從業者使用；要了解更多可用國家，請訪問：.
SOURCE UltraSight
資訊來源UltraSight
譯文內容由第三人軟體翻譯。